Takeda Pharmaceutical Company has launched Ecard, a fixed dose combination tablet of Blopress and a low-dose diuretic for treatment of hypertension.
According to Takeda, Ecard is a fixed dose combination tablet of an ARB and a diuretic, a low-dose concomitant therapy which is recommended by the guidelines for the management of hypertension in Japan.
By reducing the hydrochlorothiazide dose to 6.25mg, which is a quarter of the ordinary clinical dosage, it is believed that commonly-experienced adverse events of thiazide diuretics can be lessened. An enhancement in anti hypertensive effect was also demonstrated in the Phase III clinical trial, the company said.
Yasuhiko Yamanaka, general manager of pharmaceutical marketing division at Takeda, said: The strengths of Ecard were decided through intensive study of seeking the appropriate dosage in view of both efficacy and safety for Japanese patients with hypertension. We will vigorously provide medical professionals with scientific information of Ecard, as well as Blopress that is well supported by clinical evidences with Japanese, so that both products can contribute to reduce blood pressure.
Takeda is a research-based global pharmaceutical company. Takeda is enhancing its R&D pipeline by concentrating its management resources. Takeda’s ethical drugs are marketed in around 90 countries worldwide.